Muscle Fatigue and Carbonic Anhydrase Inhibitors

Hypoxia Clinical Trial

Official title:

The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02758470
• Other study ID #: H16-00896
• Status: Completed
• Phase: Phase 4
• Start date: November 2016
• Est. completion date: June 30, 2017

Study information

• Verified date: September 2018
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this research is to assess the effects of acetazolamide and methazolamide on respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for the respiratory and plantar flexor muscles and the difference in pressure/torque produced by supramaximal nerve stimulation used to assess muscle fatigue between conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age: 18-40 years.

• Regularly physically active

• Male

Exclusion Criteria:

• current or ex-smokers

• pulmonary function <80% of predicted

• esophageal tumour or ulcer

• have had recent (<6 months) musculoskeletal injury or any surgery to the lower leg

• have contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis)

• are obese (BMI >30 Kg/m2)

• taking diuretics, blood thinners, or anti-platelet drugs.

Related Conditions & MeSH terms

• Fatigue
• Hypoxia

Intervention

Drug:
• Acetazolamide
250 mg, taken orally three times per day
• Methazolamide
100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.

Other:
• Placebo
A placebo will be taken three times per day

Locations

Country	Name	City	State
Canada	University of British Columbia	Kelowna	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Dominelli PB, McNeil CJ, Vermeulen TD, Stuckless TJR, Brown CV, Dominelli GS, Swenson ER, Teppema LJ, Foster GE. Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial. J Appl Physiol (1985). 2018 Sep — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Esophageal and Gastric Pressure		Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol
Other	Heart Rate		Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol
Other	Beat-by-beat blood pressure		Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol
Primary	Change in trans-diaphragmatic pressure generation to supramaximal phrenic nerve stimulation following inspiratory threshold loading.		Baseline, 1, 5, 10, 20, and 30 minutes following the loading protocol for each arm of the study
Primary	Change in plantar flexor muscle group torque generation to supramaximal tibial nerve stimulation following an isometric loading protocol		Baseline, 1, 5, 10, 20, and 30 minutes following the loading protocol for each arm of the study
Secondary	Maximal inspiratory pressure maneuvers		Baseline and immediately following loading protocol
Secondary	Maximal Voluntary Contraction of the Plantar Flexor Muscle Group		Baseline and immediately following the loading protocol
Secondary	Contraction time and half-relaxation time		Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol